Targeted therapies for systemic sclerosis (Q38097276)

28 August 2017

title

Targeted therapies for systemic sclerosis (English)

1 reference

28 August 2017

Christopher P Denton

1

1 reference

28 August 2017

Voon H Ong

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

9 April 2013

1 reference

Nature Reviews Rheumatology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

8

1 reference

28 August 2017

page(s)

451-464

1 reference

Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Animal models of systemic sclerosis: prospects and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Epigenetics and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Unraveling the genetic component of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Possible strategies for anti-fibrotic drug intervention in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Involvement of functional autoantibodies against vascular receptors in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Scleroderma renal crisis: patient characteristics and long-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Effects of bosentan on nondigital ulcers in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Platelet-derived serotonin links vascular disease and tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Molecular pathogenesis of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Adenosine receptors in wound healing, fibrosis and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Pharmacological blockade of adenosine A2A receptors diminishes scarring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Adenosine A2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

LPA1 receptor activation promotes renal interstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Asthma phenotypes and interleukin-13--moving closer to personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Notch-3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Integrins as therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

A polymorphism in the CTGF promoter region associated with systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Association between a CTGF gene polymorphism and systemic sclerosis in a French population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Clinical and serological hallmarks of systemic sclerosis overlap syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Familial autoimmunity in systemic sclerosis -- results of a French-based case-control family study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Epigenetic patterns in systemic sclerosis and their contribution to attenuated CD70 signaling cascades

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Autoantibodies as predictive tools in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Stem cells: HSCT for systemic sclerosis--swallows and summers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Sustained improvement of diffuse systemic sclerosis following human cytomegalovirus infection offers insight into pathogenesis and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Pomalidomide is effective for prevention and treatment of experimental skin fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Increased interleukin-17 production in patients with systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

TGF-β-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Effect of resveratrol on treatment of bleomycin-induced pulmonary fibrosis in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.46

Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice

31 March 2020

1 reference

12 December 2020

Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis

1 reference

12 December 2020

Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts.

1 reference

12 December 2020

Clinical trial design in scleroderma: where are we and where do we go next?

1 reference

12 December 2020

Notch induces myofibroblast differentiation of alveolar epithelial cells via transforming growth factor-{beta}-Smad3 pathway

1 reference

12 December 2020

Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.46

1 reference

Dimensions Publication ID

28 August 2017

1044423494

0 references

1 reference